DYAI — Dyadic International, Inc.

Summary of Dyadic International, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.09 million for FY 2025, down from $3.5 million in 2024, primarily due to lower R&D collaboration activity and reduced license and milestone revenue.
• Grant Revenue: Increased by $1.86 million, largely from the Gates Foundation and CEPI.
• Cost of R&D Revenue: Decreased to $600,000 from $1.2 million in 2024.
• Internal R&D Expenses: Slightly increased to $2.16 million from $2.04 million.
• General & Administrative Expenses: Decreased to $5.76 million from $6.13 million.
• Loss from Operations: Increased to $7.19 million from $5.9 million year-over-year.
• Net Loss: $7.36 million, or $0.23 per share, compared to a net loss of $5.81 million, or $0.20 per share in 2024.
• Cash Position: Approximately $8.6 million at year-end, with net cash used in operating activities around $5.7 million.

2. Strategic Updates and Business Highlights

• Transitioning from a development-stage to a commercial, product-driven biotechnology business.
• Rebranding to Dyadic Applied Biosolutions and aligning the organization around commercialization.
• Key partnerships established, including collaborations with ProLiant Health for recombinant human albumin and IVT BioServices for animal-free recombinant products.
• Product launches include recombinant albumin, transferrin, and DNase I, with initial sales recorded in 2025.
• Expansion into food and nutrition markets with agreements for animal-free proteins, such as alpha-lactalbumin and lactoferrin.

3. Forward Guidance and Outlook

• Anticipates growth in product revenues across life sciences and food and nutrition markets in 2026, driven by new product launches.
• Plans to maintain operating expenses generally in line with 2025 levels while prioritizing high-impact R&D programs.
• Existing cash resources expected to provide a runway into 2027, with potential for additional capital through partnerships and market activities.
• The company aims for increasing repeat orders and revenue growth as products move into routine use.

4. Bad News, Challenges, or Points of Concern

• Declining total revenue year-over-year raises concerns about the pace of commercialization and market adoption.
• Increased operational losses indicate a need for careful cash management and potential reliance on external funding.
• The competitive landscape in biotechnology and food sectors may pressure pricing and margins, particularly as markets become more price-sensitive.
• The company faces risks related to the regulatory environment and market acceptance of animal-free products.

5. Notable Q&A Insights

• Product Revenue Ramp: Joseph Hazelton indicated a slow ramp-up in product revenues as companies qualify new products for their workflows, with expectations for significant growth as adoption increases.
• Licensing Agreements: The potential for upfront license fees varies by product and market readiness, with a focus on securing higher upfront revenues for more developed products.
• Manufacturing Capacity: There is a noted shift towards onshoring manufacturing, but challenges remain in meeting cost metrics compared to overseas production.
• Breakeven Timeline: While there is no definitive timeline for reaching breakeven, management emphasized the importance of long-term product control and commercialization strategy.
• Market Trends: There is a growing demand for animal-free proteins driven by regulatory scrutiny and market shifts, which Dyadic aims to capitalize on through its product offerings.

Overall, Dyadic International is in a transitional phase, focusing on commercialization while navigating challenges in revenue generation and market competition. The company remains optimistic about future growth driven by strategic partnerships and product launches.